Eikon Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals: Major
  • ISIN: US2825641036
USD
9.63
0.12 (1.26%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

111.16 k

Shareholding (Mar 2026)

FII

0.29%

Held by 3 FIIs

DII

99.71%

Held by 2 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals: Major

stock-summary
Market cap

USD 531 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.89

stock-summary
Return on Equity

-999,999.00%

stock-summary
Price to Book

2.25

Revenue and Profits:
Net Sales:
(Quarterly Results - Mar 2026)
Net Profit:
-83 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.93%
0%
-12.93%
6 Months
0%
0%
0.0%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Eikon Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
2.03%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
2.52%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.25
EV to EBIT
-1.23
EV to EBITDA
-1.36
EV to Capital Employed
12.74
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1037.76%
ROE (Latest)
-103.18%

Technicals key factors

Indicator
Weekly
Monthly
MACD
RSI
Bollinger Bands
KST
Dow Theory
Bearish
OBV
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (1.8%)

Foreign Institutions

Held by 3 Foreign Institutions (0.29%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Eikon Therapeutics, Inc."
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -32.98% vs -0.74% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-314.80",
          "val2": "-235.00",
          "chgp": "-33.96%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-324.20",
          "val2": "-243.80",
          "chgp": "-32.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-314.80
-235.00
-33.96%
Interest
0.80
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-324.20
-243.80
-32.98%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -32.98% vs -0.74% in Dec 2024

stock-summaryCompany CV
About stock-summary
stock-summary
Company Coordinates stock-summary
Company Details
stock-summary
Tel:
stock-summary
stock-summary
Registrar Details